scholarly journals A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico—A systematic review and meta-analysis (2008–2019)

2021 ◽  
Vol 20 ◽  
pp. 100292
Author(s):  
Virginia Sedeño-Monge ◽  
Saul Laguna-Meraz ◽  
Gerardo Santos-López ◽  
Arturo Panduro ◽  
Francisca Sosa-Jurado ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Hcv Infection ◽  
The Status

Association of chronic hepatitis C virus infection with an increased risk of lung cancer: A systematic review and meta-analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13562-e13562
Author(s):  
Ben Ponvilawan ◽  
Nipith Charoenngam ◽  
Pongprueth Rujirachun ◽  
Phuuwadith Wattanachayakul ◽  
Surapa Tornsatitkul ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Search Strategy ◽  
Meta Analysis ◽  
Hcv Infection ◽  
Increased Risk ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

e13562 Background: Chronic hepatitis C virus (HCV) infection is associated with increased risk of multiple types of extrahepatic cancer, such as lymphomas, thyroid cancer and renal cancer. However, whether HCV infection also increases the risk of lung cancer is still inconclusive. This systematic review and meta-analysis was performed in order to determine the relationship between chronic HCV infection and lung cancer. Methods: A systematic review was performed using EMBASE and MEDLINE databases from inception to November 2019 with search strategy that represents “hepatitis C virus” and “cancer”. Eligible studies must be cohort studies which include patients with chronic HCV infection and comparators without HCV infection, then follow them for incident lung cancer. Relative risk, incidence rate ratio (IRR), standardized incidence ratio, or hazard risk ratio of this association along with associated 95% confidence interval (CI) from each study were extracted and combined for the calculation of the pooled effect estimate using the random effect, generic inverse variance. Results: 20,459 articles were discovered using the aforementioned search strategy. After two rounds of review, eight studies fulfilled the inclusion criteria and were included into the meta-analysis. Chronic HCV infection was significantly associated with increased risk of lung cancer with the pooled relative risk of 1.94 (95% CI, 1.56 – 2.42; I2 = 87%). Funnel plot was fairly symmetric and not suggestive of presence of publication bias. Conclusions: Chronic HCV infection is significantly associated with a 1.94-fold increased risk in the development of lung cancer compared to no infection.

scholarly journals Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis

1970 ◽  
Vol 29 (1) ◽  
Author(s):  
Meysam Behzadifar ◽  
Sanaz Heydarvand ◽  
Masoud Behzadifar ◽  
Nicola Luigi Bragazzi
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Final Analysis ◽  
Hcv Infection ◽  
Cochrane Library ◽  
And Gender

BACKGROUND: Infection with Hepatitis C Virus (HCV) increases the hepatotoxicity of anti-tuberculosis drugs. The purpose of this systematic review and meta-analysis is to determine the prevalence of HCV infection in patients with tuberculosis (TB).METHODS: PubMed/MEDLINE, ISI/Web of Sciences, CINAHL, EMBASE, the Cochrane Library and Scopus were searched from January 2000 to March 2018. The overall prevalence of HCV in patients with TB was calculated using the random-effect model with 95% confidence interval (CI). To evaluate heterogeneity, I2 test was used. Egger's regression test was utilized to check publication bias.RESULTS: Twenty-one articles were selected for the final analysis based on the inclusion/exclusion criteria. A total of 15,542 patients with TB participated in the studies. The overall prevalence of HCV infection in patients with TB was 7% [95%CI: 6-9]. Subgroup analysis revealed that diagnostic test (P=0.0039), geographical background (P=0.0076) and gender distribution (P=0.0672) were statistically significant moderators. Men had a higher risk for HCV than women (Odds Ratio, OR=2.02; 95%CI: 1.28-3.18).CONCLUSION: The results of this study highlighted the importance of screening HCV in TB patients. Knowing whether HCV is present or not in these patients can be helpful in effectively treating them. 

Distinct Clinical Features and Prognostic Factors in Hepatitis C Virus-Associated Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Minyue Zhang ◽  
Fei Gao ◽  
Ling Peng ◽  
Lijing Shen ◽  
Peng Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prognostic Factors ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Clinical Features ◽  
Clinical Characteristics ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Hcv Infection ◽  
Free Survival

Abstract Background: Increasing evidence suggested that hepatitis C virus (HCV) infection was associated with non-Hodgkin’s lymphoma (NHL). However, no clear consensus has been reached about the clinical features and the effective treatment in HCV-associated NHL patients. We therefore performed a systematic review and meta-analysis to explore the clinical characteristics and effect of antiviral treatment or rituximab administration in NHL patients with HCV infection.Methods: PubMed, Embase, Web of Science, and OVID database were searched for eligible studies up to Feb 28, 2021. Hazard ratio (HR) or odds ratio (OR) corresponding to 95% confidence interval (CI) were calculated to estimate outcomes. Publication biases were assessed by Egger's test and Begg's test. Statistical analysis was performed by software RevMan 5.4 and Stata version 15.Results: There were 27 shortlisted articles out of a total of 13368 NHL patients included in the current meta-analysis. Our results demonstrated that NHL patients with HCV infection showed significantly shorter overall survival (OS: HR 1.89; 95% CI 1.42-2.51, P<0.0001) and progress-free survival (PFS: HR 1.58; 95% CI 1.26-1.98, P<0.0001), lower overall response rate (ORR: OR 0.58, 95% CI 0.46-0.73, P<0.00001) and higher incidence of hepatic dysfunction during chemotherapy (OR 5.96; 95% CI 2.61-13.62, P<0.0001) compared with NHL patients without HCV infection. HCV-positive NHL patients exhibited advanced disease stage, elevated level of LDH, high-intermediate and high IPI/FLIPI risk as well as higher incidence of spleen and liver involvement. Moreover, antiviral treatment could prolong survivals (OS: HR 0.38; 95% CI 0.24-0.60, P<0.0001), reduce disease progression [PFS/DFS (disease-free survival): HR 0.63; 95% CI 0.46-0.86, P=0.003] and reinforce treatment response (ORR: OR 2.62; 95% CI 1.34-5.11, P=0.005) in HCV-infected NHL patients. Finally, rituximab administration was associated with a favorable OS while liver cirrhosis and low levels of albumin were inferior prognostic factors of OS for HCV-positive NHL patients. Conclusions: The current study provided the compelling evidence about an inferior prognosis and distinct clinical characteristics in HCV-associated NHL patients. Antiviral treatment and rituximab-containing regimes were shown to be efficacious to improve clinical outcomes of NHL patients with HCV infection.

scholarly journals Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Minyue Zhang ◽  
Fei Gao ◽  
Ling Peng ◽  
Lijing Shen ◽  
Peng Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Clinical Features ◽  
Clinical Characteristics ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Hcv Infection ◽  
Hodgkin's Lymphoma ◽  
Free Survival

Abstract Background Increasing evidence suggests that hepatitis C virus (HCV) infection is associated with non-Hodgkin’s lymphoma (NHL). However, no clear consensus has been reached about the clinical features and effective treatment of HCV-associated NHL patients. We therefore performed a systematic review and meta-analysis to explore the clinical characteristics and effectiveness of antiviral treatment or rituximab administration among NHL patients with HCV infection. Methods Eight electronic databases, including PubMed, OVID, EMBASE, Cochrane Library, ClinicalTrials, WANFANG, CNKI, and VIP, were searched for eligible studies up to July 31, 2021. The hazard ratio (HR) or odds ratio (OR) corresponding to the 95% confidence interval (CI) was calculated to estimate the outcomes. Publication bias was assessed by Egger’s and Begg’s tests. Statistical analysis was performed with RevMan 5.4 software and Stata version 15. Results There were 27 shortlisted articles out of a total of 13,368 NHL patients included in the current meta-analysis. Our results demonstrated that NHL patients with HCV infection had a significantly shorter overall survival (OS: HR 1.89; 95% CI 1.42–2.51, P < 0.0001) and progression-free survival (PFS: HR 1.58; 95% CI 1.26–1.98, P < 0.0001), a lower overall response rate (ORR: OR 0.58, 95% CI 0.46–0.73, P < 0.00001) and a higher incidence of hepatic dysfunction during chemotherapy (OR 5.96; 95% CI 2.61–13.62, P < 0.0001) than NHL patients without HCV infection. HCV-positive NHL patients exhibited an advanced disease stage, an elevated level of LDH, a high-intermediate and high IPI/FLIPI risk as well as a higher incidence of spleen and liver involvement. Moreover, antiviral treatment prolonged survival (OS: HR 0.38; 95% CI 0.24–0.60, P < 0.0001), reduced disease progression [PFS/DFS (disease-free survival): HR 0.63; 95% CI 0.46–0.86, P = 0.003] and reinforced the treatment response (ORR: OR 2.62; 95% CI 1.34–5.11, P = 0.005) among the HCV-infected NHL patients. Finally, rituximab administration was associated with a favourable OS, while liver cirrhosis and low levels of albumin predicted a poor OS for HCV-positive NHL patients. Conclusions The current study provided compelling evidence about an inferior prognosis and distinct clinical characteristics among HCV-associated NHL patients. Antiviral treatment and rituximab-containing regimens were shown to be efficacious in improving the clinical outcomes of NHL patients with HCV infection.

scholarly journals The associations between Toll-like receptor 4 gene polymorphisms and hepatitis C virus infection: a systematic review and meta-analysis

2019 ◽  
Vol 39 (2) ◽  
Author(s):  
Narttaya Chaiwiang ◽  
Teera Poyomtip
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
In Silico ◽  
Meta Analysis ◽  
In Silico Analysis ◽  
Hcv Infection ◽  
Toll Like Receptor ◽  
Silico Analysis

Abstract Background and objective: The hepatitis C virus (HCV) is able to cause a life-threatening disease relating to lethal hepatocellular carcinoma. Previous, Toll-like receptor polymorphisms were proposed as promising biomarker for HCV-related hepatocellular carcinoma and disease progression. This study aimed to summarize the association of TLR4 polymorphisms and HCV infection through meta-analysis. Methods: We applied a systematic review and meta-analysis performed by using PubMed, EMBASE and Web of Science searches. The Modified Newcastle-Ottawa scale was used for quality assessment. The odd-ratio (OR) and 95% confidence interval (CI) were calculated to assess the association. In silico analysis was applied for proposing the function as microRNA (miRNA) of non-coding polymorphism. Finally, the miRNA target was predicted and annotated to suggest the possible relationship between polymorphism and HCV infection. Results: Our meta-analysis incorporated seven studies involving rs4986791, rs4986790 and rs2149356. No association exists between rs4986791 and HCV infection. However, the heterozygous model (AG vs GG) of rs4986790 significantly associates with HCV infection (OR = 0.33, 95% CI = 0.21–0.49, P<0.0001). Moreover, the rs2149356 TG genotype also associates with HCV infection in the over-dominant model (TG vs TT+TG: OR = 0.54, 95% CI = 0.40–0.75). In silico analysis of rs2149356G allele showed that this mutation is siRNA, which targets the set of genes, especially in the autophagy pathway. Conclusion: We demonstrated that rs4986790 and rs2149356 are associated with HCV infection.

scholarly journals The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Zhongyu Jian ◽  
Yucheng Ma ◽  
Hong Li ◽  
Kunjie Wang
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Bladder Cancer ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Cohort Studies ◽  
Meta Analysis ◽  
Cell Cancer ◽  
Hcv Infection ◽  
Inverse Association

Abstract Background: To update the current evidence on whether hepatitis C virus (HCV) infection represents a possible risk factor for renal cell cancer (RCC), prostate cancer (PCa) and bladder cancer (BC). Methods: We searched literatures on Pubmed, Web of Science and Embases before February 2020. A systematic review and meta-analysis were performed. Results: Finally, we extracted 12 studies based on the eligible criteria. Across 11 studies for HCV and RCC, the incorporated RR was 1.28 (95% CI 1.05-1.55), which meant that participants with HCV infection were associated with a higher risk of RCC. The pooled RR in hazard ratio (HR) subgroup (HR 1.59, 95% CI 1.22-2.08), cohort studies (CS) subgroup (RR 1.47, 95% CI 1.18-1.82), and North America subgroup (RR 1.71, 95% CI 1.40-2.09) detected a stronger association between HCV and RCC risk. Although an inverse association was seen for PCa (RR 0.75, 95% CI 0.54-1.03) across 7 studies, it was not statistically significant (P = 0.075). There was no significant association between HCV and BC with an incorporated RR of 0.92 (95% CI, 0.82-1.03) across 5 studies.Conclusions: Our study demonstrated that HCV infection was significantly associated with increased RCC risk. There appeared to be an inverse association for HCV in PCa risk but no statistically significant. No significant association was found between HCV and BC risk. Prospective, large-scale and well-designed cohort studies are required to validate the association between HCV and RCC, and to investigate the role of HCV on PCa.

Sign in / Sign up

Export Citation Format

Share Document